Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $640.00 Price Target at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by BMO Capital Markets from $600.00 to $640.00 in a research note published on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on REGN. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective for the company. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. Finally, Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a report on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $571.54 on Monday. The company has a current ratio of 5.39, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $61.71 billion, a price-to-earnings ratio of 14.40, a price-to-earnings-growth ratio of 2.10 and a beta of 0.33. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,211.20. The business has a 50 day simple moving average of $537.72 and a 200-day simple moving average of $601.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.56 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after acquiring an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. Finally, Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 3.4% in the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after acquiring an additional 52,166 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.